Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Roche buys US...

    Roche buys US Foundation Medicine for 2.4 billion dollar

    Written by Ruby Khatun Khatun Published On 2018-06-22T09:45:18+05:30  |  Updated On 22 Jun 2018 9:45 AM IST
    Roche buys US Foundation Medicine for 2.4 billion dollar

    Geneva: Swiss pharmaceutical giant Roche said it had reached an agreement to purchase the remaining shares of US lab Foundation Medicine, of which it already holds a majority stake, for $2.4 billion.


    Roche said it had agreed to pay shareholders in the US company, which is specialized in the molecular analysis and genomic profiling aimed at transforming cancer care, $137 per share.


    This represents a 29-percent premium on the closing price for Foundation Medicine (FMI) Monday evening and a 68-percent premium on the company's 90-day weighted average share price, Roche said.


    The overall transaction thus amounts to $2.4 billion, with FMI, of which Roche already held a 57-percent stake, valued at $5.3 billion, the statement said.


    The boards of both companies have unanimously approved the merger agreement.


    Roche, the world's top cancer drugmaker, said it aimed to close the deal by the end of the year.


    "This is important to our personalized healthcare strategy," said Daniel O'Day, head of Roche's pharmaceutical unit.


    "We believe molecular insights and the broad availability of high quality comprehensive genomic profiling are key enablers for the development of, and access to, new cancer treatments," he said in the statement.


    FMI, which is based in Cambridge, Massachusetts, will continue to function as an autonomous entity, he said.


    Analysts hailed the deal, with Stefan Schneider of Vontebel saying it "fits very well with Roche's personalized healthcare strategy."


    He pointed out in an investment note that the Swiss company was an "early leader in the field".


    Investors too appeared pleased with the move.


    Following the announcement, Roche saw its share price rise 0.79 percent in midday trading to 211.65 Swiss francs a piece, as the Swiss stock exchange's main SMI index slipped 0.66 percent.

    agreementbuyscancerDaniel O'DayFoundation MedicineMajority stakemergerRocheUSUS lab Foundation Medicine
    Source : AFP

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok